The SPACER Trial - Repair of Tricuspid Valve Regurgitation Using the Edwards TricuSPid TrAnsCatheter REpaiR System (SPACER)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02787408 |
Recruitment Status :
Completed
First Posted : June 1, 2016
Results First Posted : October 25, 2022
Last Update Posted : October 25, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tricuspid Valve Regurgitation | Device: EW Tricuspid Transcatheter Repair System | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The SPACER Trial - Repair of Tricuspid Valve Regurgitation Using the Edwards TricuSPid TrAnsCatheter REpaiR System |
Actual Study Start Date : | September 14, 2016 |
Actual Primary Completion Date : | January 30, 2018 |
Actual Study Completion Date : | December 14, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: EW Tricuspid Transcatheter Repair System
Edwards (EW) Tricuspid Transcatheter Repair System
|
Device: EW Tricuspid Transcatheter Repair System
Treatment with the EW Tricuspid Transcatheter Repair System |
- All-cause Mortality [ Time Frame: At 30 days. ]The primary endpoint for the study will assess the all-cause mortality of the as treated cohort at 30 days compared to a literature derived Performance Goal based on high-risk surgical outcomes for tricuspid repair/replacement. Due to the early termination of the study, the desired statistical power was not attained and thus this comparison analysis was not performed. All-cause mortality is presented below as a number of deaths and percentage of patients only.
- Technical Success [ Time Frame: Implant Procedure ]
Alive, with
- Successful access, delivery and removal of the delivery systems, and
- Deployment and correct positioning of the intended device, and
- No need for additional emergency surgery or re-intervention related to the device or access procedure
- Device Success [ Time Frame: At 1 month, 6 months, 1, 2, and 3 years ]
Alive, with
- Original intended device in place, and
- No additional surgical or interventional procedures related to the device, and
- Tricuspid Regurgitation (TR) reduction compared to baseline and Tricuspid Valve (TV) gradient ≤ 5 mmHg
- Procedural Success [ Time Frame: At 1 month ]
Device Success, and
None of the following device or procedure related Serious Adverse Events (SAE):
- Life threatening bleeding
- Major vascular or cardiac structural complications requiring intervention
- Pericardial effusion requiring drainage or surgery (includes tamponade)
- Stage 2 or 3 acute kidney injury (includes new dialysis).
- Severe heart failure or hypotension requiring Intravenous (IV) inotrope, ultrafiltration or mechanical circulatory support
- Prolonged intubation > 48 hours
- Clinical Outcomes [Heart Failure Re-Hospitalization Rates] [ Time Frame: At 1 month, 6 months, 1, 2 and 3 years ]Re-hospitalization rates for the underlying condition (heart failure)
- Clinical Outcomes [Tricuspid Regurgitation Re-Intervention Rates] [ Time Frame: At 1 month, 6 months, 1, 2 and 3 years ]Re-intervention rates for the underlying condition (tricuspid regurgitation)
- Clinical Outcomes [Changes in Peripheral Edema] [ Time Frame: At 1 month, 6 months, 1, 2 and 3 years ]Change in peripheral edema as assessed by subject weight loss (kilograms) compared to baseline
- Clinical Outcomes [Change in New York Heart Association (NYHA) Class] [ Time Frame: At 1 month, 6 months, 1, 2 and 3 years ]
Change in New York Heart Association (NYHA) Class compared to baseline
Measure Description:
Measure Description: NYHA Classification - The stages of heart failure:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest.
Class IV - Severe limitations. Experiences symptoms even while at rest.
- Clinical Outcomes [Change in 6 Minute Walk Test Distance] [ Time Frame: At 1 month, 6 months, 1, 2 and 3 years ]Change in 6 minute walk test distance (meters) compared to baseline
- Clinical Outcomes [Change in Quality of Life Short Form (SF)-12 Questionnaire] [ Time Frame: At 1 month, 6 months, 1, 2 and 3 years ]Change in Quality of Life as assessed by the Short Form (SF)-12 questionnaire compared to baseline The SF-12 is a short survey with 12 questions that results in two scales of mental and physical functioning and overall health related quality of life. The SF-12 Score is scaled from 0-100, with higher scores indicating better physical and mental health functioning.
- Clinical Outcomes [Change in Quality of Life Kansas City Cardiomyopathy Questionnaire (KCCQ)] [ Time Frame: At 1 month, 6 months, 1, 2 and 3 years ]Change in Quality of Life as assessed by the KCCQ questionnaire compared to baseline The KCCQ is a 12-item questionnaire that quantifies physical limitations, symptoms, self-sufficiency, social interaction and quality of life. The KCCQ scale is 0-100. An increase in the KCCQ-12 score reflects an improvement in symptoms for the subject. A mean difference over time of 5 points on the KCCQ-12 summary score reflects a clinically significant change in heart failure status.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed and dated Ethics Committee (EC) approved study consent form prior to study related procedures
- Eighteen years of age or older
- Clinically significant, symptomatic (New York Heart Association (NYHA) Functional Class II or greater), tricuspid regurgitation (per applicable guidelines) requiring tricuspid valve repair or replacement as assessed by the Heart Team
- Functional tricuspid regurgitation as the primary etiology
- New York Heart Association (NYHA) Functional Class II or greater or signs of persistent right heart failure despite optimal medical therapy
- Determined by the 'HEART Team' (a minimum of one Cardiologist, and one Cardiac Surgeon) to be at high surgical risk for tricuspid valve repair or replacement and the benefit-risk analysis supports utilization of the investigational device
- Willing to attend study follow-up assessments for up to 3 years
Exclusion Criteria
-
Tricuspid valve/right heart anatomy not suitable for the study device:
- Native tricuspid annulus area < 2.14 cm2 (9 mm device) or < 2.63 cm2 (12 mm device) or < 3.27cm2 (15 mm device) as measured by transthoracic echocardiography
- Sub-valvular structures/anatomy that would preclude from proper anchor or coaptation device placement, positioning and retrieval
- Access pathway vessel diameter less than 7.1 mm (9, 12 mm and 15 mm devices)
- Moderate or greater tricuspid valve stenosis
- Untreated clinically significant coronary artery disease requiring immediate revascularization
- Any therapeutic invasive cardiac procedure performed within 30 days of the scheduled implant procedure
- Patients not already receiving dialysis with renal insufficiency (eGFR <25) per lab test ≤ 48 hours prior to scheduled implant procedure
- Myocardial infarction within 30 days of scheduled implant procedure
- Hemodynamic instability within 30 days of scheduled implant procedure
- Patient requiring surgery under general anesthesia for any reason within 90 days of scheduled implant procedure
- Severe left ventricular dysfunction with ejection fraction < 25% within 90 days of scheduled implant procedure
- Patients with pulmonary artery systolic pressure > 70 mmHg via transthoracic echocardiography or alternative standard modality (e.g., direct pressure measurement) within 90 days
- Concomitant clinically significant valve (aortic, mitral, or pulmonic) disease requiring immediate (± 30 days of study procedure) repair or replacement
- Active endocarditis or infection within 3 months of scheduled implant procedure
- Cerebrovascular accident within 3 months of scheduled implant procedure
- Non-cardiac disease limiting life expectancy to be less than 12 months at baseline evaluation
- Documented history of bleeding diathesis, coagulopathy or gastrointestinal bleeding within 3 months of scheduled implant procedure
- Evidence of right sided intracardiac mass, thrombus, or vegetation
- Prior venous stent placed within the access route (e.g., sub-clavian vein) that could negatively react with device
- Previously treated tricuspid valve which included implantation of a bioprosthetic valve or mechanical valve
- Known hypersensitivity to cobalt chromium, nitinol or titanium
- Known hypersensitivity to anticoagulation therapy or contrast agent, which cannot be adequately medicated
- Patient is a current intravenous drug user
- Female of child-bearing potential is pregnant or lactating
- Patient is currently participating or has participated in another investigational drug or device clinical study within 30 days of study screening activity
- Patient requires emergent/emergency treatment for tricuspid insufficiency
- Patient is under guardianship

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02787408
Canada, British Columbia | |
St. Paul's Hospital, Providence Health Care Research Institute | |
Vancouver, British Columbia, Canada, V6E 1M7 | |
Canada, Ontario | |
Toronto General Hospital | |
Toronto, Ontario, Canada, M5G 2C4 | |
Canada | |
Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite Laval | |
Quebec, Canada, G1V 4G5 | |
France | |
Institut Hospitalier Jacques Cartier | |
Massy, France, 91300 | |
Hōpital Charles Nicolle | |
Rouen, France, 76031 | |
Germany | |
Universitäts-Herzzentrum Freiburg - Bad Krozingen | |
Bad Krozingen, Germany, 79189 | |
Charite-Universitätsmedzin Berlin | |
Berlin, Germany, 10117 | |
Asklepios Klinik St. Georg | |
Hamburg, Germany, 20099 | |
Munich University Clinic, Ludwig-Maximilian University | |
Munich, Germany, 81377 | |
Greece | |
Hygeia Hospital | |
Athens, Greece, 15123 | |
Switzerland | |
Inselspital, Universitätsspital Bern | |
Bern, Switzerland, 3010 |
Documents provided by Edwards Lifesciences:
Responsible Party: | Edwards Lifesciences |
ClinicalTrials.gov Identifier: | NCT02787408 |
Other Study ID Numbers: |
2015-09 |
First Posted: | June 1, 2016 Key Record Dates |
Results First Posted: | October 25, 2022 |
Last Update Posted: | October 25, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Tricuspid Valve Insufficiency Heart Valve Diseases Heart Diseases Cardiovascular Diseases |